News

Italy and Greece are the two countries that were granted the longest transition period of 6 years for the implementation of the Falsified Medicines Directive. Accordingly, from February 9, 2025, the European Medicines Verification System must also be operational in these countries, where active preparations are currently underway.

Study supporting the report on trends in the falsification of medicinal products and measures provided according to Directive 2011/62/EU.

2023. gada beigās Somijas Zāļu verifikācijas organizācija (FiMVO) nomainīja zāļu verifikācijas sistēmas (FiMVS) piegādātāju. Piegādātājs tika nomainīts no Arvato uz Solidsoft Reply (SSR). Šī pārmaiņa bija pirmais šāda veida gadījums Eiropas Zāļu verifikācijas sistēmas (EMVS) ekosistēmā. Tā iezīmēja nozīmīgu brīdi FiMVO misijā nodrošināt farmaceitiskās piegādes ķēdes integritāti un drošību Somijā.

On May 23, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2024 from the National Medicines Verification Organizations (NMVOs) were approved. Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane were re-elected as observers for the second consecutive year, representing the small countries group.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.21)”.

The European Medicines Verification Organisation (EMVO) has launched the EMVS Community Newsletter - edition April 2024. This month, newsletter focusing on Data Quality, featuring insights from EMVO, the Dutch NMVO, Accord Healthcare, and end-user perspectives from the healthcare sector.